Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ev3 Inc.
Enrollment begun for embolic protection device in carotid clinical trial
April 26th, 2005
Ev3 Inc., a privately held endovascular medical device company, has received approval to include the SpideRX Embolic Protection Device in the second arm of the company's carotid clinical trial. Embolic protection devices are small filters placed within a blood vessel to capture and remove plaque particles dislodged during interventional procedures, such as angioplasty or stenting, to prevent stroke or heart attack. Ev3 has completed enrollment in the first phase of this trial using the Spider Embolic Device and the Protege GPS Self-Expanding Stent. The 30-day results of the first phase will be presented in a trials session at the Society of...
Source: Cardiovascular Business Week (2005-04-26)
|
